OPRA vs. AZN

Last updated Apr 2, 2026

Compare and contrast key facts about Opera Limited (OPRA) and AstraZeneca PLC (AZN).

Performance

OPRA vs. AZN - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Opera Limited (OPRA) and AstraZeneca PLC (AZN). The values are adjusted to include any dividend payments, if applicable.

OPRA vs. AZN - Yearly Performance Comparison

	2026 (YTD)	2025	2024	2023	2022	2021	2020	2019	2018
OPRA Opera Limited	5.27%	-22.08%	52.02%	140.60%	-10.91%	-22.67%	-1.30%	66.37%	-57.59%
AZN AstraZeneca PLC	11.46%	43.30%	-0.62%	1.44%	19.14%	19.66%	3.12%	35.68%	0.50%

Fundamentals

Market Cap OPRA : $1.32B AZN : $313.54B
EPS OPRA : $1.19 AZN : $6.55
PE Ratio OPRA : 12.15 AZN : 30.64
PEG Ratio OPRA : 0.05 AZN : 0.04
PS Ratio OPRA : 2.14 AZN : 5.33
PB Ratio OPRA : 1.31 AZN : 6.44
Total Revenue (TTM) OPRA : $614.60M AZN : $58.74B
Gross Profit (TTM) OPRA : $359.92M AZN : $48.11B
EBITDA (TTM) OPRA : $109.91M AZN : $19.83B

Returns By Period

In the year-to-date period, OPRA achieves a 5.27% return, which is significantly lower than AZN's 11.46% return.

OPRA

• 1D: 1.68%
• 1M: -6.15%
• YTD: 5.27%
• 6M: -24.25%
• 1Y: -5.71%
• 3Y*: 18.38%
• 5Y*: 12.04%
• 10Y*: —

AZN

• 1D: 1.78%
• 1M: -1.47%
• YTD: 11.46%
• 6M: 21.46%
• 1Y: 42.12%
• 3Y*: 15.74%
• 5Y*: 17.86%
• 10Y*: 16.92%

*Multi-year figures are annualized to reflect compound growth (CAGR)

Return for Risk

OPRA vs. AZN — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

OPRA

OPRA Risk / Return Rank: 36
OPRA Sharpe Ratio Rank: 35
OPRA Sortino Ratio Rank: 35
OPRA Omega Ratio Rank: 35
OPRA Calmar Ratio Rank: 37
OPRA Martin Ratio Rank: 37

AZN

AZN Risk / Return Rank: 84
AZN Sharpe Ratio Rank: 85
AZN Sortino Ratio Rank: 82
AZN Omega Ratio Rank: 80
AZN Calmar Ratio Rank: 87
AZN Martin Ratio Rank: 85

The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

OPRA vs. AZN - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for Opera Limited (OPRA) and AstraZeneca PLC (AZN). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

	OPRA	AZN	Difference
Sharpe ratio Return per unit of total volatility	-0.10	1.56	-1.66
Sortino ratio Return per unit of downside risk	0.26	2.25	-2.00
Omega ratio Gain probability vs. loss probability	1.03	1.29	-0.26
Calmar ratio Return relative to maximum drawdown	-0.11	3.25	-3.36
Martin ratio Return relative to average drawdown	-0.20	8.16	-8.36
Data is calculated on a 1-year rolling basis and updated daily. The trend shows the change in the indicator over the past month.

OPRA vs. AZN - Sharpe Ratio Comparison

The current OPRA Sharpe Ratio is -0.10, which is lower than the AZN Sharpe Ratio of 1.56. The chart below compares the historical Sharpe Ratios of OPRA and AZN, offering insights into how both investments have performed under varying market conditions. These values are calculated using daily returns over the previous 12 months.

Sharpe Ratios by Period

	OPRA	AZN	Difference
Sharpe Ratio (1Y) Calculated over the trailing 1-year period	-0.10	1.56	-1.66
Sharpe Ratio (5Y) Calculated over the trailing 5-year period	0.19	0.75	-0.56
Sharpe Ratio (10Y) Calculated over the trailing 10-year period	—	0.68	—
Sharpe Ratio (All Time) Calculated using the full available price history	0.08	0.51	-0.43

Correlation

The correlation between OPRA and AZN is 0.09, which is considered to be low. This implies their price changes are not closely related. A low correlation is generally favorable for portfolio diversification, as it helps to reduce overall risk by spreading it across multiple assets with different performance patterns.

Dividends

OPRA vs. AZN - Dividend Comparison

OPRA's dividend yield for the trailing twelve months is around 5.52%, more than AZN's 2.65% yield.

	TTM	2025	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015
OPRA Opera Limited	5.52%	5.65%	4.22%	8.92%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
AZN AstraZeneca PLC	2.65%	1.70%	2.27%	2.15%	2.12%	2.35%	2.80%	2.81%	3.69%	3.95%	5.01%	4.06%

Drawdowns

OPRA vs. AZN - Drawdown Comparison

The maximum OPRA drawdown since its inception was -72.85%, which is greater than AZN's maximum drawdown of -48.94%. Use the drawdown chart below to compare losses from any high point for OPRA and AZN.

Drawdown Indicators

	OPRA	AZN	Difference
Max Drawdown Largest peak-to-trough decline	-72.85%	-48.94%	-23.91%
Max Drawdown (1Y) Largest decline over 1 year	-41.28%	-12.24%	-29.04%
Max Drawdown (5Y) Largest decline over 5 years	-68.16%	-27.87%	-40.29%
Max Drawdown (10Y) Largest decline over 10 years	—	-27.87%	—
Current Drawdown Current decline from peak	-40.72%	-3.70%	-37.02%
Average Drawdown Average peak-to-trough decline	-40.94%	-11.38%	-29.56%
Ulcer Index Depth and duration of drawdowns from previous peaks	22.76%	4.88%	+17.88%

Volatility

OPRA vs. AZN - Volatility Comparison

Opera Limited (OPRA) has a higher volatility of 10.71% compared to AstraZeneca PLC (AZN) at 7.15%. This indicates that OPRA's price experiences larger fluctuations and is considered to be riskier than AZN based on this measure. The chart below showcases a comparison of their rolling one-month volatility.

Volatility by Period

	OPRA	AZN	Difference
Volatility (1M) Calculated over the trailing 1-month period	10.71%	7.15%	+3.56%
Volatility (6M) Calculated over the trailing 6-month period	40.02%	19.20%	+20.82%
Volatility (1Y) Calculated over the trailing 1-year period	54.68%	27.33%	+27.35%
Volatility (5Y) Calculated over the trailing 5-year period, annualized	62.23%	23.85%	+38.38%
Volatility (10Y) Calculated over the trailing 10-year period, annualized	64.78%	24.90%	+39.88%

Financials

OPRA vs. AZN - Profitability Comparison

The chart below illustrates the profitability comparison between Opera Limited and AstraZeneca PLC over time, highlighting three key metrics: Gross Profit Margin, Operating Margin, and Net Profit Margin.

OPRA - Gross Margin

Gross margin is calculated as gross profit divided by revenue. For the three months ending on Apr 2026, Opera Limited reported a gross profit of 76.51M and revenue of 176.99M. Therefore, the gross margin over that period was 43.2%.

AZN - Gross Margin

Gross margin is calculated as gross profit divided by revenue. For the three months ending on Apr 2026, AstraZeneca PLC reported a gross profit of 12.39B and revenue of 15.50B. Therefore, the gross margin over that period was 79.9%.

OPRA - Operating Margin

Operating margin is calculated as operating income divided by revenue. For the three months ending on Apr 2026, Opera Limited reported an operating income of 29.46M and revenue of 176.99M, resulting in an operating margin of 16.6%.

AZN - Operating Margin

Operating margin is calculated as operating income divided by revenue. For the three months ending on Apr 2026, AstraZeneca PLC reported an operating income of 2.98B and revenue of 15.50B, resulting in an operating margin of 19.2%.

OPRA - Net Margin

Net margin is calculated as net income divided by revenue. For the three months ending on Apr 2026, Opera Limited reported a net income of 55.64M and revenue of 176.99M, resulting in a net margin of 31.4%.

AZN - Net Margin

Net margin is calculated as net income divided by revenue. For the three months ending on Apr 2026, AstraZeneca PLC reported a net income of 2.33B and revenue of 15.50B, resulting in a net margin of 15.0%.